Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300336 | 0.89 | GLA (0.39) | GLASMN1; SMN2BACE1CYP1A2CYP2C9 | |
| SCHEMBL3293995 | 0.84 | CALM1 (0.38) | SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL3295598 | 0.83 | LTA4H (0.44) | GLASMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3294303 | 0.81 | KDM4E (0.45) | GLASMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13462924 | 0.80 | BIRC5 (0.51) | GLASMN1; SMN2BACE1CYP1A2CYP2C9 | |
| SCHEMBL3298757 | 0.79 | PTGS2 (0.48) | SMN1; SMN2CYP1A2ATM | |
| SCHEMBL3298753 | 0.78 | KDM4E (0.44) | SMN1; SMN2CYP1A2CYP2C9CYP2C19TLR8 | |
| SCHEMBL3296160 | 0.77 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19ATMTLR8 | |
| SCHEMBL3299743 | 0.77 | CYP1A2 (0.40) | GLASMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10873504 | 0.76 | S1PR2 (0.49) | GLASMN1; SMN2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741393-B2 | Organic silicon-based compound and method of producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | ARSA, OR10J3, HDAC10 | GLA 304/4885SMN1; SMN2 1035/4885BACE1 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.